All News
Understanding Comorbidities in RMD
2026 EULAR Press Release
People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. The 2026 EULAR Congress showcased new data and ideas around various comorbidities and drug safety issues in people with an RMD – highlighting the need for integrated care. Here are five abstracts to consider.
Read Article
Count Your Telangiectasias (5.29.2026)
Dr. Jack Cush reviews the news, journal articles and missed quiz questions.
Read Article
EGPA Review
A current review of eosinophilic granulomatosis with polyangiitis (EGPA) provides current recommendations on diagnosis and management.
Read Article
Gout Control Lowers Cardiovascular Events
A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.
Read Article
#OP091 at #EULAR2026: RA was associated with a 44% higher risk of ischaemic stroke versus the general population, with higher stroke-related mortality and disability. Encouragingly, excess stroke risk was no longer significant in more recent RA cohorts. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#OP088 at #EULAR2026 found that rare deleterious variants in telomere-related genes were associated with increased RA-ILD risk, independent of MUC5B status. The effect size was similar to that seen in idiopathic pulmonary fibrosis. @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
#Autoimmune #progressive #pulmonary #fibrosis
Large Spanish registry
❎more mortality if not on #DMARDs
?underRx of proven #Rx with #antifibrotics
Median survival post #dx #PPF 7.8 yrs
Can we do better?
#ABST POS0430
@RheumNow #EULAR2026 https://t.co/gP7apxfEPS
Links:
Janet Pope Janetbirdope ( View Tweet)
Kicking off Clinical Abstracts: Comorbidities in RA session at #EULAR2026 with #OP084
ANCHOR-RA found 9.1% at-risk RA patients had previous undiagnosed ILD on screening HRCT. Older age, smoking, male sex & ⬆️DAS28 linked to RA-ILD. Important data for earlier detection @RheumNow
Mrinalini Dey DrMiniDey ( View Tweet)
Does #Rx w #immunesuppression w
#antifibrotic
Help #SARD-ILD?
YES.
N=40 SARD-ILD, 1/2 w UIP pattern
Use of #IS w #antifibrotic pt group had better survival
Small N and ?channeling bias
But interesting results
TAke home : Use IS + antifibrotic
#EULAR2026 #POS0530
@RheumNow https://t.co/tfxVVw27jJ
Janet Pope Janetbirdope ( View Tweet)
RA comorbidities are changing. ILD, anxiety, depression increasing. Less extraartic. manifestations, CA & CV dz. Consider screening for cervical CA, ILD, CV dz & OP (for pts on steroids) https://t.co/WVITFXNva7 https://t.co/tggdaO9RJB
Dr. John Cush RheumNow ( View Tweet)
Hopkins study of HCQ in discoid lupus (DLE) - 5 yr outcomes of 106 adult DLE; those on HCQ had less hyperlipidemia (HL), PAD, angina, & CAD. Parallel TriNetX study showed HCQ assoc w/ signif less HTN, HL, DM, CAD, & CVA. https://t.co/yX7FkGCnvR https://t.co/oddq68FYeE
Links:
Dr. John Cush RheumNow ( View Tweet)
10yr retrosp. study of 110 Still’s dz pts. MAS occurred in 37% (1/2 @onset; assoc w/ serositis) and ILD observed in 82% (also assoc w/ MAS, polycyclic course) https://t.co/SNa0KiWfgY https://t.co/xbpCuHdJka
Dr. John Cush RheumNow ( View Tweet)
RA adds to mortality risk in nontuberculous mycobact. infx (NTM). Retro study 1420 NTM pts, 66 (4.6) had RA. RA was independent predictor of resp-death (HR 4.30) - partly explained by ILD & systemic inflammation https://t.co/S9bndHsXCE https://t.co/mC74Qve1LZ
Dr. John Cush RheumNow ( View Tweet)
Predictors of renal crisis & pulm. arterial HTN (PAH) in systemic sclerosis - retrospect. study of 234 SSc pts; 7.3% had PAH & SRC. PAH may precede overlap w/ SRC. SSc w/ both at hi risk for GI bleed (OR 9.5). SRC+PAH assoc w/ Older age, elevated NT-proBNP https://t.co/MsaiPdcDrb https://t.co/CyMrL8izxP
Dr. John Cush RheumNow ( View Tweet)
Gout Control Lowers Cardiovascular Events
A large target emulation trial suggests that gout patients prescribed urate-lowering treatment who achieve a serum urate level lower than 6 mg/dL significantly lower their risk of cardiovascular events.
https://t.co/LcBg7yCw4c https://t.co/dBYdnq9XLJ
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Factor as a Potential Marker of Cardiometabolic and Hepatic Risk. RF has been assoc w/ ASHD, MI, CAD, ischemic stroke, obesity, insulin resistance, type 2 diabetes, and metabolic syndrome -- all mediated via downstream inflammation. https://t.co/gQvqMJmyPw https://t.co/8VnmVsuU2h
Dr. John Cush RheumNow ( View Tweet)
Metabolic Syndrome Predicts Cardiovascular Outcomes in Inflammatory Arthritis
In this prospective observational study 811 CIA patients analyze outcomes in patients with and without MetS, including cardiovascular death/hospitalization and all-cause death/hospitalization. https://t.co/WT3wTpeGPi
Dr. John Cush RheumNow ( View Tweet)
Global trends in systemic sclerosis (SSc) mortality. Betw 2001-23, in 74 countries, 85,291 SSc deaths (79% females). While SSc-Crude mortality increased from 1.97 (2001) to 2.34 (2023), the age-standardized mortality decreased from 1.58 to 1.29. declining in Americas & Europe. https://t.co/lvHbF5HLPY
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Factor as a Potential Marker of Cardiometabolic and Hepatic Risk. RF has been assoc w/ ASHD, MI, CAD, ischemic stroke, obesity, insulin resistance, type 2 diabetes, and metabolic syndrome -- all mediated via downstream inflammation. https://t.co/gQvqMJmyPw https://t.co/TmoodnuJTe
Dr. John Cush RheumNow ( View Tweet)
24 systemic amyloidosis pts (AA type 46%, AL 29%); 62% joint pain & AM stiff, axial 37.5%, macroglossia (4 pts, 17%), carpal tunnel (12%), proteinuria > 1 gm 50%, CKD 21%, Cardiac amyloid 29%. Amyloid was secondary to Rheum Dx in 11/24. Better survival w/ AA than AL (91% vs https://t.co/pAEqYJIKaw
Dr. John Cush RheumNow ( View Tweet)
